- Barrons.com•15 days ago
Keryx Biopharmaceuticals (KERX:Nasdaq) By Maxim Group ($6.98, July 8, 2016) We spoke with Keryx Biopharmaceuticals management and left our conversation upbeat. The new Keryx (KERX) salesforce -- 95 reps and 11 regional managers, with the majority (two-thirds) being new -- is now in place and should be having an impact. This, combined with recent positive news flow (chronic kidney disease (CKD) trial), should begin to translate into quarterly revenue growth.
Keryx Biopharmaceuticals Inc.NasdaqCM
After hours: 7.420.00 (0.02%) as of 4:41 PM EDT
|Bid||6.88 x 100|
|Ask||7.61 x 500|
|52wk Range||2.80 - 8.31|
|Day's Range||7.38 - 7.51|
|Avg Vol (3m)||1,380,793|
As of 4:00 PM EDT. Market closed.